SCHEMBL20197187

SCHEMBL20197187

CS(=O)(=O)Nc1cc(I)ccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
KDM4E B2RXH2 5/20 0.40
HPGD P15428 2/20 0.40
SLC22A12 Q96S37 1/20 0.40
ALOX15 P16050 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
PIK3C3 Q8NEB9 1/20 0.38
KMT2A Q03164 1/20 0.38
LMNA P02545 1/20 0.38
TYK2 P29597 1/20 0.37
IKBKB O14920 1/20 0.37
CHUK O15111 1/20 0.37
KDM4D Q6B0I6 1/20 0.37
HTT P42858 1/20 0.37
GLO1 Q04760 1/20 0.37
TGFBR1 P36897 2/20 0.36
BUB1 O43683 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12460797 0.79 KDM4E (0.59) ALDH1A1KDM4EHPGDKMT2ALMNA
SCHEMBL27167048 0.78 ABL1 (0.47) ALDH1A1KDM4EHPGDSLC22A12ALOX15
SCHEMBL21617733 0.78 BRD4 (0.49) ALDH1A1KDM4EHPGDSLC22A12LMNA
SCHEMBL20197168 0.77 PTGS1 (0.48) SLC22A12
SCHEMBL12203063 0.75 ALDH1A1 (0.52) ALDH1A1KDM4EHPGDSLC22A12ALOX15
SCHEMBL4636523 0.75 SLC22A12 (0.44) ALDH1A1KDM4EHPGDSLC22A12ALOX15
SCHEMBL12228985 0.75 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDSLC22A12ALOX15
SCHEMBL25847426 0.75 KDM4E (0.51) ALDH1A1KDM4EHPGDSLC22A12KMT2A
SCHEMBL2730632 0.74
SCHEMBL23020774 0.74 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDSLC22A12ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 EP disclosed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 CN disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 WO disclosed
EP-3038622-B1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECH LLC (US) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB ALDH1A1 4083/4885KDM4E 1442/4885HPGD 2408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.